Hu Tengpeng, Wang Xinhua, Yu Chang, Yan Jiaqin, Zhang Xundong, Li Ling, Li Xin, Zhang Lei, Wu Jingjing, Ma Wang, Li Wencai, Wang Guannan, Zhao Wugan, Gao Xianzheng, Zhang Dandan, Zhang Mingzhi
Lymphoma Diagnosis and Treatment Center, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ;
Oncol Lett. 2013 May;5(5):1467-1476. doi: 10.3892/ol.2013.1224. Epub 2013 Mar 4.
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm arising most commonly from follicular dendritic cells in the lymph nodes. It is exceedingly rare in extranodal sites, particularly in the pharyngeal region. The present study reports 3 cases occurring in the pharyngeal region. Case 1 had tonsil and cervical lymph node involvement, while case 3 also had tonsil involvement. Cases 1 and 3 relapsed locally at 3 and 17 months after surgery, respectively. Case 2 was diagnosed with a tumor in the parapharyngeal space and the patient succumbed to the disease 5 months after treatment with combined surgery and chemotherapy. All 3 cases were misdiagnosed initially. Pathological biopsy examination, including histopathology and immunohistochemistry, was essential for diagnosis. The data for 52 cases, including cases from the literature and the present cases, were analyzed. The results indicated that 57% (26/46) of the initial diagnoses were inaccurate, while the recurrence, metastasis and mortality rates were 40, 16 and 10%, respectively. The statistics supported the theory that FDCS of the pharyngeal region is a low-grade sarcoma. Involvement of the tonsils (52%, 27/52) and parapharyngeal space (19%, 10/52) were observed most commonly, while FDCS at various sites showed different prognoses. The various survival rates were calculated in the present study. The large tumors (≥4 cm) had a poorer prognosis than the small tumors (<4 cm; P<0.05). Among the 50 cases with available follow-up data, 46% (23/50) were treated with surgery alone, 52% (26/50) with combination therapy (surgery followed by chemotherapy and/or radiotherapy) and 2% (1/50) with surveillance. There was no statistically significant evidence (P>0.05) that combination therapy improves survival rates, compared with surgery alone.
滤泡性树突状细胞肉瘤(FDCS)是一种罕见肿瘤,最常见于淋巴结中的滤泡性树突状细胞。在结外部位极为罕见,尤其是在咽部区域。本研究报告了3例发生在咽部区域的病例。病例1累及扁桃体和颈部淋巴结,病例3也累及扁桃体。病例1和病例3分别在术后3个月和17个月局部复发。病例2诊断为咽旁间隙肿瘤,患者在接受手术和化疗联合治疗5个月后死于该病。所有3例最初均被误诊。包括组织病理学和免疫组织化学在内的病理活检检查对诊断至关重要。分析了52例病例的数据,包括文献报道的病例和本研究中的病例。结果表明,57%(26/46)的初始诊断不准确,而复发率、转移率和死亡率分别为40%、16%和10%。这些统计数据支持了咽部区域FDCS是一种低级别肉瘤的理论。最常观察到累及扁桃体(52%,27/52)和咽旁间隙(19%,10/52),而不同部位的FDCS显示出不同的预后。本研究计算了各种生存率。大肿瘤(≥4 cm)的预后比小肿瘤(<4 cm;P<0.05)差。在有可用随访数据的50例病例中,46%(23/50)仅接受手术治疗,52%(26/50)接受联合治疗(手术 followed by 化疗和/或放疗),2%(1/50)接受观察。与单纯手术相比,没有统计学显著证据(P>0.05)表明联合治疗能提高生存率。